MONSTER BEVERAGE CORP
MNSTNASDAQ🏆 #153 by market capEarnings Oct 29 · PostUS Equity
$45.66▲ $0.22 (+0.48%)
🌙 After hours$46.45▲ 1.73%Regular close · extended-hours price shownTrack MNST
Get earnings, price moves & breaking news on Telegram
24h▲ 0.5%
7d▼ 2.1%
14d▲ 3.2%
30d▲ 9.1%
ytd▲ 19.1%
1y▲ 31.7%
🏦Market Cap
$89.31B
Mid Cap
📈Revenue Growth (YoY)
20.4%
Healthy
📊Gross Margin
55.5%
Healthy
💵FCF Margin
22.8%
Strong
⚖️P/S Ratio
9.8x
Elevated
Otter Score
76
Strong
MONSTER BEVERAGE CORP
MNSTAnalyst Ratings
Price
$45.66
Total
44
Raised
6
Lowered
7
Avg PT
$84.68
H / L
$104 / $50
| Institution | Action | Rating | Date | Upside | |
|---|---|---|---|---|---|
Wells Fargo | Reiterated | Overweight | 2026-10-26 | $50.00 | +9.50% |
JP Morgan | Reiterated | Neutral | 2026-10-26 | — | — |
Evercore ISI Group | Reiterated | Outperform | 2026-08-07 | — | — |
UBS | Reiterated | Neutral | 2026-08-07 | $104.00 | +127.80% |
RBC Capital | Reiterated | Outperform | 2026-08-07 | $97.00 | +112.40% |
Piper Sandler | Reiterated | Overweight | 2026-08-07 | $50.50 | +10.60% |
BMO Capital | Reiterated | Market Perform | 2026-07-20 | $95.00 | +108.10% |
Deutsche Bank | Downgraded | Buy → Hold | 2026-07-20 | $100.00 | +119.00% |
Stifel | Reiterated | Buy | 2026-07-16 | — | — |
Citigroup | Reiterated | Buy | 2026-07-14 | $98.00 | +114.60% |
Morgan Stanley | Reiterated | Overweight | 2026-06-01 | $103.00 | +125.60% |
Rothschild & Co | Upgraded | Neutral → Buy | 2026-05-06 | — | — |
TD Cowen | Reiterated | Hold | 2026-01-08 | — | — |
B of A Securities | Reiterated | Buy | 2025-11-07 | — | — |
Roth Capital | Reiterated | Neutral | 2025-08-13 | $70.00 | +53.30% |
Redburn Atlantic | Downgraded | Buy → Neutral | 2025-07-09 | — | — |
Roth MKM | Reiterated | Neutral | 2025-05-14 | — | — |
CICC | Upgraded | Market Perform → Outperform | 2025-05-12 | — | — |
Truist Securities | Reiterated | Sell | 2025-04-24 | — | — |
Needham | Reiterated | Hold | 2025-02-28 | — | — |
HSBC | Reiterated | Buy | 2024-03-06 | — | — |
MKM Partners | Reiterated | Neutral | 2023-08-10 | — | — |
Goldman Sachs | Reiterated | Buy | 2023-05-05 | $67.00 | +46.70% |
Wedbush | Reiterated | Neutral | 2023-03-30 | $95.00 | +108.10% |
Argus Research | Reiterated | Buy | 2023-03-21 | $95.00 | +108.10% |
Redburn Partners | Upgraded | Neutral → Buy | 2023-03-06 | $90.00 | +97.10% |
Bernstein | Upgraded | Market Perform → Outperform | 2022-05-18 | $95.00 | +108.10% |
Credit Suisse | Reiterated | Outperform | 2022-02-18 | $110.00 | +140.90% |
Jefferies | Downgraded | Buy → Hold | 2021-10-13 | $100.00 | +119.00% |
Guggenheim | Upgraded | Neutral → Buy | 2020-03-20 | — | — |
SunTrust Robinson Humphrey | Reiterated | Buy | 2020-02-28 | — | — |
Cowen & Co. | Downgraded | Outperform → Market Perform | 2019-10-17 | — | — |
Macquarie | Downgraded | Outperform → Neutral | 2019-04-01 | — | — |
Stifel Nicolaus | Reiterated | Buy | 2018-09-18 | $52.00 | +13.90% |
Susquehanna | Downgraded | Neutral → Negative | 2017-11-20 | — | — |
Bank of America | Reiterated | Neutral | 2016-03-22 | — | — |
CLSA | Reiterated | Outperform → Buy | 2016-02-26 | — | — |
ISI Group | Reiterated | Buy | 2014-09-22 | — | — |
Longbow Research | Upgraded | Underperform → Neutral | 2014-08-08 | — | — |
BTIG Research | Reiterated | Buy | 2014-06-19 | — | — |
Northcoast Research | Reiterated | Sell | 2013-08-23 | — | — |
Gabelli & Co. | Downgraded | Buy → Hold | 2013-05-09 | — | — |
ValuEngine | Reiterated | Strong Buy | 2012-11-27 | — | — |
Canaccord Genuity | Reiterated | Hold | 2012-05-10 | — | — |
Institution
Wells Fargo
Reiterated · Overweight · 2026-10-26
$50.00
+9.50%
JP Morgan
Reiterated · Neutral · 2026-10-26
—
—
Evercore ISI Group
Reiterated · Outperform · 2026-08-07
—
—
UBS
Reiterated · Neutral · 2026-08-07
$104.00
+127.80%
RBC Capital
Reiterated · Outperform · 2026-08-07
$97.00
+112.40%
Piper Sandler
Reiterated · Overweight · 2026-08-07
$50.50
+10.60%
BMO Capital
Reiterated · Market Perform · 2026-07-20
$95.00
+108.10%
Deutsche Bank
Downgraded · Buy → Hold · 2026-07-20
$100.00
+119.00%
Stifel
Reiterated · Buy · 2026-07-16
—
—
Citigroup
Reiterated · Buy · 2026-07-14
$98.00
+114.60%
Morgan Stanley
Reiterated · Overweight · 2026-06-01
$103.00
+125.60%
Rothschild & Co
Upgraded · Neutral → Buy · 2026-05-06
—
—
TD Cowen
Reiterated · Hold · 2026-01-08
—
—
B of A Securities
Reiterated · Buy · 2025-11-07
—
—
Roth Capital
Reiterated · Neutral · 2025-08-13
$70.00
+53.30%
Redburn Atlantic
Downgraded · Buy → Neutral · 2025-07-09
—
—
Roth MKM
Reiterated · Neutral · 2025-05-14
—
—
CICC
Upgraded · Market Perform → Outperform · 2025-05-12
—
—
Truist Securities
Reiterated · Sell · 2025-04-24
—
—
Needham
Reiterated · Hold · 2025-02-28
—
—
HSBC
Reiterated · Buy · 2024-03-06
—
—
MKM Partners
Reiterated · Neutral · 2023-08-10
—
—
Goldman Sachs
Reiterated · Buy · 2023-05-05
$67.00
+46.70%
Wedbush
Reiterated · Neutral · 2023-03-30
$95.00
+108.10%
Argus Research
Reiterated · Buy · 2023-03-21
$95.00
+108.10%
Redburn Partners
Upgraded · Neutral → Buy · 2023-03-06
$90.00
+97.10%
Bernstein
Upgraded · Market Perform → Outperform · 2022-05-18
$95.00
+108.10%
Credit Suisse
Reiterated · Outperform · 2022-02-18
$110.00
+140.90%
Jefferies
Downgraded · Buy → Hold · 2021-10-13
$100.00
+119.00%
Guggenheim
Upgraded · Neutral → Buy · 2020-03-20
—
—
SunTrust Robinson Humphrey
Reiterated · Buy · 2020-02-28
—
—
Cowen & Co.
Downgraded · Outperform → Market Perform · 2019-10-17
—
—
Macquarie
Downgraded · Outperform → Neutral · 2019-04-01
—
—
Stifel Nicolaus
Reiterated · Buy · 2018-09-18
$52.00
+13.90%
Susquehanna
Downgraded · Neutral → Negative · 2017-11-20
—
—
Bank of America
Reiterated · Neutral · 2016-03-22
—
—
CLSA
Reiterated · Outperform → Buy · 2016-02-26
—
—
ISI Group
Reiterated · Buy · 2014-09-22
—
—
Longbow Research
Upgraded · Underperform → Neutral · 2014-08-08
—
—
BTIG Research
Reiterated · Buy · 2014-06-19
—
—
Northcoast Research
Reiterated · Sell · 2013-08-23
—
—
Gabelli & Co.
Downgraded · Buy → Hold · 2013-05-09
—
—
ValuEngine
Reiterated · Strong Buy · 2012-11-27
—
—
Canaccord Genuity
Reiterated · Hold · 2012-05-10
—
—
One row per institution · price target from the firm's latest published target